This inventor holds 4 USPTO granted patents and 7 published patent applications. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2020-2025.
Location History:
- Cumberland, RI (US) (2021)
- Yardley, PA (US) (2020 - 2022)
Company Filing History:
3 out of 3,735 
Years Active: 2020-2025
Title: Michael Louis Doyle: Innovator in Fusion Protein Technology
Introduction
Michael Louis Doyle is a prominent inventor based in Yardley, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 4 patents to his name, Doyle's work has the potential to impact therapeutic applications significantly.
Latest Patents
Doyle's latest patents focus on Interleukin-2/interleukin-2 receptor alpha fusion proteins and their methods of use. These patents disclose fusion proteins that comprise a first polypeptide consisting of Interleukin-2 (IL2) and a second polypeptide that includes an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα). Notably, either IL2 or IL2Rα contains at least one fewer glycosylation site compared to their native forms. The patents also detail methods of production and therapeutic applications for these innovative fusion proteins.
Career Highlights
Michael Louis Doyle is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research in biotechnology. His work is characterized by a commitment to developing novel therapeutic solutions that leverage the unique properties of fusion proteins.
Collaborations
Doyle collaborates with esteemed colleagues, including Mary Struthers and Jonathan Harry Davis. These partnerships enhance the innovative potential of his research and contribute to the advancement of the field.
Conclusion
Michael Louis Doyle stands out as a key figure in the development of fusion protein technology. His innovative patents and collaborations reflect his dedication to advancing therapeutic applications in biotechnology.